Blood Biomarkers May Help ID Primary CNS Lymphoma, High-Grade Glioma
MONDAY, April 18, 2022 (HealthDay News) -- Systemic inflammatory biomarkers may aid in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG), according to a study published online April 4 in CNS Oncology.
Tejpal Gupta, M.D., from the Homi Bhabha National Institute in Mumbai, India, and colleagues calculated systemic inflammatory indices from pretreatment complete blood counts and liver function tests and compared them against histopathology as a reference standard among 42 patients with PCNSL and 16 with HGG.
The researchers observed significant differences in the mean values for absolute lymphocyte count and prognostic nutritional index between PCNSL and HGG patients. For absolute lymphocyte count and prognostic nutritional index, the area under the receiver operating characteristic curve in the diagnosis of PCNSL was 0.70 and 0.72, respectively, indicating fair and acceptable diagnostic accuracy.
"This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging," the authors write.
Related Posts
New Ways to Spot Risk for CTE in Boxers, MMA Fighters
THURSDAY, June 29, 2023 (HealthDay News) -- Autopsy is currently the only way to...
¿Esa cuna o cochecito de segunda mano son seguros? La mayoría de los padres no lo saben, según una encuesta
LUNES, 15 de mayo de 2023 (HealthDay News) -- Los equipos para los bebés pueden...
El ejercicio puede ayudar a reducir la peligrosa grasa que rodea al hígado
LUNES, 13 de febrero de 2023 (HealthDay News) -- Con frecuencia, se aconseja a...
Los nuevos refuerzos de Pfizer protegen de las variantes emergentes de la ómicron
VIERNES, 18 de noviembre de 2022 (HealthDay News) -- Las vacunas de refuerzo...